Search results
Merck KGaA abandons Phase III trial for $1.08bn head & neck cancer drug
Pharmaceutical Technology· 6 days agoFollowing the news of trial termination, Merck’s stock was down by over 10% in trading on the ...
Following the news of trial termination, Merck’s stock was down by over 10% in trading on the ...